secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001213900-23-038131
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q1 revenue down 5% to $13.0M; GAAP EPS loss $(0.37), non-GAAP loss $(0.09)
--------------------------------------------------------------------------------

- Total revenue $13.0M, down 5% from $13.7M a year ago; gross profit $7.4M (-8% YoY).
- GAAP net loss $(6.4)M or $(0.37) per share vs. $(3.8)M or $(0.21) last year.
- Non-GAAP net loss $(1.6)M or $(0.09) per share vs. $(0.1)M or $(0.01) last year.
- Reaffirms FY2023 guidance: net revenue growth at least 10% YoY, gross margins 58-62%.
- Rolling 12-month net revenue retention fell to 86% from 124%; avg revenue per top 20 pharma co. down to ~$1.99M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/0001213900-23-038131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023038131/ea178286-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer